Overview

A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma

Status:
Recruiting

Trial end date:
2027-06-10

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, tolerability, and preliminary anti-tumor activity of forimtamig when administered alone or in combination with carfilzomib or daratumumab or other combination partners in participants with relapsed or refractory multiple myeloma (r/r MM). The study consists of two phases: a dose exploration phase and a dose-expansion phase.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Hoffmann-La Roche

Treatments:

Daratumumab